These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 33057069)
1. Application of small molecule FPR1 antagonists in the treatment of cancers. Ahmet DS; Basheer HA; Salem A; Lu D; Aghamohammadi A; Weyerhäuser P; Bordiga A; Almeniawi J; Rashid S; Cooper PA; Shnyder SD; Vinader V; Afarinkia K Sci Rep; 2020 Oct; 10(1):17249. PubMed ID: 33057069 [TBL] [Abstract][Full Text] [Related]
2. The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis. Snapkov I; Öqvist CO; Figenschau Y; Kogner P; Johnsen JI; Sveinbjørnsson B BMC Cancer; 2016 Jul; 16():490. PubMed ID: 27432059 [TBL] [Abstract][Full Text] [Related]
3. Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Pinilla C; Edwards BS; Appel JR; Yates-Gibbins T; Giulianotti MA; Medina-Franco JL; Young SM; Santos RG; Sklar LA; Houghten RA Mol Pharmacol; 2013 Sep; 84(3):314-24. PubMed ID: 23788657 [TBL] [Abstract][Full Text] [Related]
4. Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo. Korinek M; Hsieh PS; Chen YL; Hsieh PW; Chang SH; Wu YH; Hwang TL Biochem Pharmacol; 2021 Aug; 190():114596. PubMed ID: 33964283 [TBL] [Abstract][Full Text] [Related]
5. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion. Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus. Boer JC; Domanska UM; Timmer-Bosscha H; Boer IG; de Haas CJ; Joseph JV; Kruyt FA; de Vries EG; den Dunnen WF; van Strijp JA; Walenkamp AM Br J Cancer; 2013 Feb; 108(3):587-96. PubMed ID: 23322202 [TBL] [Abstract][Full Text] [Related]
7. Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models. Francavilla F; Sarcina F; Schepetkin IA; Kirpotina LN; Contino M; Schirizzi A; De Leonardis G; Khlebnikov AI; D'Alessandro R; Quinn MT; Lacivita E; Leopoldo M Eur J Med Chem; 2023 Dec; 261():115854. PubMed ID: 37839346 [TBL] [Abstract][Full Text] [Related]
9. The Expression of Formyl Peptide Receptor 1 is Correlated with Tumor Invasion of Human Colorectal Cancer. Li SQ; Su N; Gong P; Zhang HB; Liu J; Wang D; Sun YP; Zhang Y; Qian F; Zhao B; Yu Y; Ye RD Sci Rep; 2017 Jul; 7(1):5918. PubMed ID: 28724995 [TBL] [Abstract][Full Text] [Related]
10. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889 [TBL] [Abstract][Full Text] [Related]
11. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Liu M; Zhao J; Chen K; Bian X; Wang C; Shi Y; Wang JM Int Immunopharmacol; 2012 Nov; 14(3):283-8. PubMed ID: 22863814 [TBL] [Abstract][Full Text] [Related]
12. The leukocyte chemotactic receptor FPR1 is functionally expressed on human lens epithelial cells. Schneider EH; Weaver JD; Gaur SS; Tripathi BK; Jesaitis AJ; Zelenka PS; Gao JL; Murphy PM J Biol Chem; 2012 Nov; 287(48):40779-92. PubMed ID: 23012360 [TBL] [Abstract][Full Text] [Related]
13. The peptidomimetic Lau-(Lys-βNSpe) Skovbakke SL; Winther M; Gabl M; Holdfeldt A; Linden S; Wang JM; Dahlgren C; Franzyk H; Forsman H Biochem Pharmacol; 2016 Nov; 119():56-65. PubMed ID: 27614010 [TBL] [Abstract][Full Text] [Related]
14. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones. Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672 [TBL] [Abstract][Full Text] [Related]
15. Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1. Liu FC; Yu HP; Syu YT; Fang JY; Lin CF; Chang SH; Lee YT; Hwang TL Sci Rep; 2017 Jul; 7(1):6718. PubMed ID: 28751674 [TBL] [Abstract][Full Text] [Related]
16. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Prevete N; Liotti F; Visciano C; Marone G; Melillo RM; de Paulis A Oncogene; 2015 Jul; 34(29):3826-38. PubMed ID: 25263443 [TBL] [Abstract][Full Text] [Related]
17. Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question. Winther M; Holdfeldt A; Sundqvist M; Rajabkhani Z; Gabl M; Bylund J; Dahlgren C; Forsman H PLoS One; 2017; 12(9):e0185132. PubMed ID: 28934373 [TBL] [Abstract][Full Text] [Related]
18. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002 [TBL] [Abstract][Full Text] [Related]
19. Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives. Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT Int Immunopharmacol; 2016 Aug; 37():43-58. PubMed ID: 26382576 [TBL] [Abstract][Full Text] [Related]